Elon Musk revealed on December 31, 2025, that Neuralink, his neurotechnology company, will begin high-volume production of its brain-computer interface (BCI) devices in 2026. In a post on X (formerly Twitter), Musk also outlined plans to transition to a streamlined, almost entirely automated surgical procedure for implanting the devices. A key advancement highlighted is that the ultra-thin electrode threads will penetrate the dura—the protective membrane covering the brain—without requiring its removal, which Musk described as “a big deal” for improving safety and scalability.
The N1 implant, roughly the size of a coin, features 64 flexible threads carrying over 1,000 electrodes that record and stimulate brain activity. Currently inserted using a precision surgical robot, the procedure is expected to become faster and more automated, potentially resembling a quick outpatient process like LASIK eye surgery in the future.
Neuralink’s progress in 2025 laid the groundwork for this scaling. The company expanded clinical trials internationally, conducting its first implants outside the U.S. in Canada and the UK, and launching trials in the UAE. It raised $650 million in funding, valuing the company at around $9 billion. As of late 2025, estimates suggest approximately 20 patients have received implants, up from 12 reported earlier in the year. These participants, many with severe paralysis or ALS, have used the device—branded as Telepathy—to control computers, play games, type by thought, and even operate robotic arms.
First recipient Noland Arbaugh, implanted in early 2024, has demonstrated long-term use, including browsing the internet and socializing online solely through neural signals. Other patients have regained abilities like gesturing, preparing food, or communicating more naturally despite progressive conditions.
Looking ahead, Musk has expressed ambition for over 1,000 implants by the end of 2026, though timelines depend on clinical outcomes and regulatory oversight from bodies like the FDA. Neuralink also plans to advance its Blindsight project, a separate implant aimed at restoring vision by stimulating the visual cortex, with first human trials anticipated in 2026. This follows FDA breakthrough device designation granted in 2024.
While initially focused on helping those with paralysis and neurological disorders regain independence, Musk envisions broader applications, including enhancing human cognition and achieving symbiosis with artificial intelligence. However, widespread availability remains tied to ongoing trials proving long-term safety and efficacy.
This announcement marks a pivotal shift for Neuralink from experimental prototypes to industrial-scale production, potentially accelerating access to brain-computer interfaces for medical needs.
About The Author
